

"The Gray Sheet"

August 02, 2010

AxioMed Spine financings

The degenerative spine disease start-up completed a "series D" funding round, collecting \$14.5 million from existing and new investors, AxioMed announced July 22. The privately-held company plans to use the funds to complete enrollment of a U.S. pivotal study for its **Freedom** lumbar disc, which has a CE mark in Europe and has been sold there for the past 12 months. The investment will also help AxioMed expand its sales force for Freedom in Europe, as well as achieve CE mark and support the launch of its cervical disc.

"Copyright © 2010 FDC Reports Inc. All Rights Reserved."